Raju Prasad - May 30, 2025 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Financial Officer
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Stock symbol
CRSP
Transactions as of
May 30, 2025
Transactions value $
$0
Form type
4
Date filed
6/3/2025, 09:45 PM
Previous filing
Mar 24, 2025
Next filing
Oct 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Prasad Raju Chief Financial Officer C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON /s/ Elizabeth Ryland Waldinger, attorney-in-fact 2025-06-03 0001968317

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Award $0 +20K $0.00 20K May 30, 2025 Common Shares 20K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2 This restricted stock unit award was granted on May 30, 2025 with respect to 20,000 Common Shares, with 100% of the shares vesting on May 30, 2028.